retatrutide receptor targets three receptors for weight loss Retatrutide + Cagrilintide: Quad-Pathway Stack

doi: 10.3389/fddsv.2026.1792418 Received 20 January 2026 Revised 11 March 2026 Accepted 16 March 2026 Published 10 April 2026 Volume 6 - 2026 Edited by Liang Xu, University of Kansas, United States Reviewed by Christel Menet, Confo Therapeutics, Belgium Anukriti Saran, Banasthali University, India Updates Copyright 2026 Niazi

215,216 Interestingly, PS1 overexpression reduces p53 activity, which forms a negative feedback mechanism to regulate p53 activity

People with T2D receiving these drugs had a higher body weight and baseline HbA 1c than those from RCTs [67]

People with diabetes using semaglutide should be aware of potential diabetic retinopathy complications and follow ophthalmological monitoring recommendations